Benedikt N. Eisinger

Benedikt N. Eisinger

Auto-generated profile, based on publicly available information

Benedikt N. Eisinger

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Science
Verified
Journal Article
Closed access
HLHsiu-Chuan Lin
Hsiu-Chuan Lin
JJJasper Janssens
Jasper Janssens
BEBenedikt Eisinger
Benedikt Eisinger
PHPhilipp Hornauer
Philipp Hornauer
AKAnn-Sophie Kröll
Ann-Sophie Kröll
BTBarbara Treutlein
Barbara Treutlein
Human neurons programmed through transcription factor (TF) overexpression model neuronal differentiation and disease. However, the diversity of neuronal subtypes programmable in vitro remains unresolved. We modulated developmental signaling pathways combined with TF overexpression to explore the spectrum of neuron subtypes generated from pluripotent stem cells. We screened 480 morphogen signaling modulations coupled with TF induction using a multiplexed single-cell transcriptomic readout. Analysis of 700,000 cells identified diverse excitatory and inhibitory neurons patterned along the developmental axes of the neural tube. Patterning neural progenitors prior to TF overexpression expanded neuronal diversity by enabling access to regulons active in primary tissue counterparts. Our approach provides a strategy for programming diverse human cell subtypes as well as investigating how cooperative signaling drives neuronal fate.

5 March 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
LFLester Frei
Lester Frei
BGBeichen Gao
Beichen Gao
JHJiami Han
Jiami Han
JTJoseph M. Taft
Joseph M. Taft
EIEdward B. Irvine
Edward B. Irvine
SRSai T. Reddy
Sai T. Reddy
Most antibodies for treating COVID-19 rely on binding the receptor-binding domain (RBD) of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). However, Omicron and its sub-lineages, as well as other heavily mutated variants, have rendered many neutralizing antibodies ineffective. Here we show that antibodies with enhanced resistance to the evolution of SARS-CoV-2 can be identified via deep mutational learning. We constructed a library of full-length RBDs of Omicron BA.1 with high mutational distance and screened it for binding to the angiotensin-converting-enzyme-2 receptor and to neutralizing antibodies. After deep-sequencing the library, we used the data to train ensemble deep-learning models for the prediction of the binding and escape of a panel of eight therapeutic antibody candidates targeting a diverse range of RBD epitopes. By using in silico evolution to assess antibody breadth via the prediction of the binding and escape of the antibodies to millions of Omicron sequences, we found combinations of two antibodies with enhanced and complementary resistance to viral evolution. Deep learning may enable the development of therapeutic antibodies that remain effective against future SARS-CoV-2 variants.